Table 1.
Reference for planning of pituitary adenoma and meningioma
| Pituitary adenoma | Meningioma | |
|---|---|---|
| PTV definitions | ||
| PTV = CTV + 1 mm (CTV = GTV), | PTV = CTV + 1 mm (CTV = GTV) | |
| PTV = CTV + 2 - 4 mm (CTV = GTV) | PTV = CTV + 2 - 3 mm (CTV = GTV) | |
| Prescribed dose | ||
| SRS | 15 - 20 Gy marginal dose, 25 Gy or more for secreting pituitary adenoma | 11 - 18 Gy marginal dose (recommended for 14 Gy or more) |
| Conventional fractionated SRT | isocenter 45 - 68 Gy/daily 1.8 Gy/fr., D95 50 - 56 Gy/daily 2 Gy/fr. | |
| SRT | 45 - 50 Gy/25 - 28 fr. | 2 Gy/fr. |
| Constrains for organs at risk[11] | ||
| SRS | Optic tract < 8 - 10 Gy, | |
| Conventional fractionated | ||
| SRT | Optic tract 50 Gy/25 fr | |
| Spinal cord < 50 Gy (10 cm or less in length) | ||
| Retina < 45 Gy | ||
| Lens < 10 Gy | ||
| Brain stem < 60 Gy (1/3 volume) | ||
SRS; stereotactic radiosurgery, SRT; stereotactic radiotherapy,
GTV; gross tumor volume, CTV; clinical treatment volume, PTV; planning target volume, fr.; fraction,
D95; irradiation dose that included 95% volume of PTV